Biblio
Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax. Clin Cancer Res. 2024.
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. Am J Hematol. 2020.
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2015.
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021.
Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020;4(8):1690-1699.
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019.
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. 2024.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023.
.